ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GSK Gsk Plc

1,708.60
3.40 (0.20%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.40 0.20% 1,708.60 1,708.60 1,708.80 1,713.00 1,699.40 1,701.60 8,026,989 16:29:59
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.30 70.48B

Pfizer to Acquire Two Meningitis Vaccines

22/06/2015 1:20pm

Dow Jones News


Gsk (LSE:GSK)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Gsk Charts.

Pfizer Inc. has agreed two acquire meningitis vaccines from GlaxoSmithKline PLC for about $130 million, a move to expand its global reach in preventing meningococcal disease.

New York-based Pfizer said it would buy Nimenrix and Mencevax, both single-dose meningococcal vaccines. Nimenrix, launched three years ago, is approved for sale in 61 countries outside of the U.S. Mencevax, approved in 79 countries outside of the U.S., is used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic.

The acquisitions follow Pfizer's purchase last year of Baxter International Inc.'s meningococcal disease vaccine NeisVac-C, as well as approval in the U.S. of its drug Trumenba to protect against erogroup B meningococcal disease in individuals 10 through 25 years of age.

Adding the two latest vaccines "will allow us to more completely respond to meningococcal disease outbreaks," said president for Pfizer Vaccines, Susan Silbermann.

The transaction is expected to be completed in the second half of this year and isn't expected to have any significant impact on this year's financial performance, Pfizer said.

Write to Lisa Beilfuss at lisa.beilfuss@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


1 Year Gsk Chart

1 Year Gsk Chart

1 Month Gsk Chart

1 Month Gsk Chart

Your Recent History

Delayed Upgrade Clock